Design of selective nuclear receptor modulators: RAR and RXR as a case study

Nature Reviews Drug Discovery

Volumn 6, Issue 10, 2007, Pages 811-820

  de Lera, Angel R ^a   Bourguet, William ^b,c   Altucci, Lucia ^d   Gronemeyer, Hinrich ^e  

^a UNIVERSITY OF VIGO   (Spain)

^b INSERM   (France)

^c CENTRE DE BIOCHIMIE STRUCTURALE   (France)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXY 4,14 RETRORETINOL; 4 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 ANTHRYL)BENZOIC ACID; 4 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHALENYL) 2 NAPHTHALENE CARBOXYLIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; 4 [2 [5,5 DIMETHYL 8 (2 PHENYLETHYNYL) 5,6 DIHYDRONAPHTHALEN 2 YL]ETHEN 1 YL]BENZOIC ACID; 4 [2 [5,6 DIHYDRO 5,5 DIMETHYL 8 (4 METHYLPHENYL) 2 NAPHTHYL]ETHYNYL]BENZOIC ACID; 4 AMINO 2 (BUTYRYLAMINO)PHENYLRETINAMIDE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ACYCLIC RETINOID; AGN 193918; ALITRETINOIN; AMINOAROTINOID; ANHYDRORETINOL; ANTINEOPLASTIC AGENT; BEXAROTENE; BMS 204493; CD 2674; FENRETINIDE; MOFAROTENE; MX 781; NIK 333; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR MODULATOR; RETINOIC ACID RECEPTOR STIMULATING AGENT; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOID X RECEPTOR BLOCKING AGENT; RETINOID X RECEPTOR MODULATOR; RETINOID X RECEPTOR STIMULATING AGENT; REXINOID; RO 13 7419; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; TRANSCRIPTION REGULATION;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS;

EID: 34848862778     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2398     Document Type: Review

References (59)

1. Laudet, V. & Gronemeyer, H. The Nuclear Receptor Facts Book (Academic Press, San Diego, 2002).
2. Gronemeyer, H., Gustafsson, J, A. & Laudet, V. Principles for modulation of the nuclear receptor superfamily. Nature Rev. Drug Disc. 3 950-964 (2004).
3. Mark, M., Ghyselinck, N. B. & Chambon, P. Function of retinoid nuclear receptors: Lessons from genetic and pharmacological dissections of the retinoic acid signalling pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Taxicol. 46, 451-480 (2005).
4. Upenberg, A. et al. In vivo activation of PPAR target genes by RXR, homodimers. EMBO J. 23, 2083-2091 (2004).
5. de Urquiza, A. M. et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 290, 2140-2144 (2000).
6. Lengqvist, J. et al. Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor α ligand-binding domain. Mol. Cell. Proteomics 3, 692-703 (2004).
7. Zusi, F. C., Lorenzi, M. V. & Vivat-Hannah, V. Selective retinoids and rexinoids in cancer therapy and chemo-prevention. Drug Discov. Today 7, 1165-1174 (2002).
8. Dawson, M. I. Synthetic retinoids and their nuclear, receptors. Curr. Med. Chem. Anticancer Agents 4, 199-230 (2004).
9. Bourguet, W., Cermain, P. & Gronemeyer, H. Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol. Sci. 21, 381-388 (2000).
10. Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H. & Maras, D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 375, 377-382 (1995).
11. Egea, P. F. et al. Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. EMBO J. 19, 2592-2601 (2000).
12. Wurtz, J. M. et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nature Struct. Biol. 3, 87-94 (1996).
13. Hermanson, O., Glass, C. K. & Rosenfeld, M. G. Nuclear receptor coregulators: Multiple modes of modification. Trends Endocrinol. Metab. 13, 55-60 (2002).
14. Smith, C. L. & O'Malley, B. W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
15. Wu, R. C., Smith, C. L. & O'Malley, B. W. Transcriptional regulation by steroid receptor coactivator phosphorylation. Endocr. Rev. 26 393-399 (2005).
16. Bourguet, W. et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5, 289-298 (2000).
17. Vivat, V. et al. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers. EMBO J. 16, 5697-5709 (1997).
18. Vivat-Hannah, V., Bourguet, W., Gottardis, M. & Gronemeyer, H. Separation of retinoid X receptor homo- and heterodimerization functions. Mol. Cell. Biol. 23, 7678-7688 (2003).
19. Germain, P., Iyer, J., Zechel, C. & Gronemeyer, H. Coregulator recruitment and the mechanism of retinoic acid receptor synergy. Nature 415, 187-192 (2002).
20. Gampe, R. T. Jr et al. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5, 545-555 (2000).
21. Brelivet, Y., Kammerer, S., Rachel, N., Poch, O. & Moras, D. Signature of the oligomeric behaviour of nuclear receptors at the sequence and structural level. EMBO Rep. 5, 423-429 (2004).
22. Shulman, A. I., Larson, C., Mangelsdorf, D. J. & Ranganathan, R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 116, 417-429 (2004).
23. Nettles, K. W. et al. Allosteric control of ligand selectivity between estrogen receptors α and β: Implications for other nuclear receptors. Mol. Cell 13, 317-327 (2004).
24. Aranda, A. & Pascual, A. Nuclear hormone receptors and gene expression. Physiol. Rev. 81, 1269-1304 (2001).
25. McKenna, N. J. & O'Malley, B. W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474 (2002).
26. Klein, E. S., Wang, J. W., Khalifa, B., Gavigan. S. A. & Chandraratna, R. A. Recruitment of nuclear receptor corepressor and coactivator to the retinoic acid receptor by retinoid ligands. Influence of DNA-heterodimer interactions. J. Biol. Chem. 275, 19401-19408 (2000).
27. Loeliger, P., Bollag, W. & Mayer, H. Arotinoids: A new class of highly active retinoids. Eur. J. Med. Chem. 15, 9-15 (1980).
28. Domínguez, B., Alvarez, R. & de Lera, A. R. Recent Advances in the synthesis of retinoids. Org. Prep. Proc. Int. 35, 239-306 (2003).
29. Germain, P. et al. Rational design of RAR-selective ligands revealed by RARβ crystal stucture. EMBO Rep. 5, 877-882 (2004).
30. Klein, E. S. et al. Identification and functional separation of retinoic acid receptor neutral antagonists and inverse agonists. J. Biol. Chem. 271, 22692-22696 (1996).
31. Klaholz, B. P. et al. Conformational adaptation of agonists to the human nuclear receptor RARγ. Nature Struct. Biol. 5, 199-202 (1998).
32. Harmon, M. A., Boehm, M. F., Heyman, R. A. & Mangelsdorf, D. J. Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc. Natl Acad. Sci. USA 92, 6157-6160 (1995).
33. Kitareewan, S. et al. Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol. Cell. Biol. 7, 1153-1166 (1996).
34. LeMotte, P. K., Keidek, S. & Apfel, C. M. Phytanic acid is a retinoid X receptor ligand. Eur. J. Biochem. 236, 328-333 (1996).
35. Egea, P. F. et al. Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid. EMBO J. 19, 2592-2601 (2000).
36. Egea, P. F., Mitschler, A. & Maras, D. Molecular recognition of agonist ligands by RXRs. Mol. Endocrinol. 16, 987-997 (2002).
37. Nolte, R. T. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395 137-143 (1998).
38. Uppenberg, J. et al. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J. Biol. Chem. 273 31108-31112 (1998).
39. Xu, H. E. et al. Molecular recognition of fatty acids by peroxisome proliferator- activated receptors. Mol. Cell 3, 397-403 (1999).
40. Greschik, H. et al. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol. Cell 9, 303-313 (2002).
41. Kallen, J. et al. Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor α (ERRα): Crystal structure of ERRα ligand binding domain in complex with peroxisome proliferator-activated receptor coactivator-1 α. J. Biol. Chem. 279, 49330-49337 (2004).
42. Wang, L. et al. X-ray crystal structures of the estrogen-related receptor-γ ligand binding domain in three functional states reveal the molecular basis of small molecule regulation. J. Biol. Chem. 281, 37773-37781 (2006).
43. Pissios, P., Tzameli, I., Kushner, P. & Moore, D. D. Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. Mol. Cell 6, 245-253 (2000).
44. Tamrazi, A., Carlson, K. E. & Katzenellenbogen, J. A. Molecular sensors of estrogen receptor conformations and dynamics. Mol. Endocrinol. 17, 2593-2602 (2003).
45. Kallenberger, B. C., Love, J. D., Chatterjee, V. K. & Schwabe, J. W. A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nature Struct. Biol. 10, 136-140 (2003).
46. Johnson, B. A. et al. Ligand-induced stabilization of PPARγ monitored by NMR spectroscopy: Implications for nuclear receptor activation. J. Mol. Biol. 298, 187-194 (2000).
47. Boehm, M. F. et al. Synthesis and structure-activity relationships of novel retinold X receptor-selective retinoids. J. Med. Chem. 37, 2930-2941 (1994).
48. Faul. M. M., Ratz, A. M., Sullivan, K. A., Trankle, W. G. & Winneroski, L. L. Synthesis of novel retinoid X receptor-selective retinoids. J. Org. Chem. 66, 5772-5782 (2001).
49. Gèhin, M. et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem. Biol. 6, 519-529 (1999).
50. Beard, R. L. et al. Synthesis and biological activity of retinoic acid receptor-α specific amides, Bioorg. Med. Chem. Lett. 12 3145-3148 (2002).
51. Teng, M. et al. Identification of highly potent retinoic acid receptor α-selective antagonists. J. Med. Chem. 40, 2445-2451 (1997).
52. Ostrowski, J. et al. Serine 232 and methionine 272 define the ligand binding pocket in retinoic acid receptor subtypes. J. Biol. Chem. 273, 3490-3495 (1998).
53. Yu. K-L. et al. Structural modifications of 6-naphthalene-2-carboxylate retinoids Bioarg. Med. Chem. Lett. 6, 2865-2870 (1996).
54. Klaholz, B. P., Mitschler A. & Moras, D. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J. Mol. Biol. 302, 155-170 (2000).
55. Klaholz, B. P., Mitschler, A., Belema, M., Zusi, C. & Maras, D. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγ. Proc. Natl. Acad. Sci. USA 97, 6322-6327 (2000).
56. Charpentier, B. et al. Synthesis, structure-affinity relationships. and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 38, 4993-5006 (1995).
57. Szondy, Z. et al. Induction of apoptosis by retinoids and retinoic acid receptor γ-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol. Pharmacol. 51, 972-982 (1997).
58. Zhang, L. et al. Discovery of novel retinoic acid receptor agonists having potent antiproliferative activity in cervical cancer cells. J. Med. Chem. 39, 2659-2663 (1996).
59. Dawson, M. I. et al. 4-[3-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl- 2-naphthalenylphenyl]benzoic acid and heterocyclic-bridged analogues are novel retinoic acid receptor subtype and retinoid X receptor α agonists. Bioorg. Med. Chem. Lett. 10, 1311-1313 (2000).